Brain Fog and Life Quality in Menopause

What this trial studies

This clinical study aims to investigate cognitive changes in women undergoing the menopausal transition, with a specific focus on the prevalence, characteristics, and impact of brain fog. The research will assess how declining estrogen levels influence cognitive domains such as memory, attention, and executive function across different menopausal stages (perimenopause, menopause, and postmenopause). Through a comparative and observational design, the study will evaluate the relationship between subjective cognitive complaints and menopause-specific quality of life. Findings are expected to inform the development of non-pharmacological strategies-such as lifestyle modifications and cognitive health interventions-to mitigate cognitive decline and improve overall well-being in midlife women.

Conditions in scope

• Menopause
• Cognitive Dysfunction
• Memory Disorders
• Quality of Life
• Women's Health
• Perimenopausal Disorder
• Postmenopausal Symptoms

Interventions

• Not specified in the public record.

Who can join

Women only · Ages 40 Years to 60 Years · Accepts healthy volunteers.

Inclusion criteria

• Aged between 40 and 60 years.
• In any stage of menopause.
• Able to complete the Brain Fog Scale and Menopause-Specific Quality of Life Scale due to cognitive and physical capability.
• Willing to participate in the study voluntarily.
• Able to read and write in Turkish.

Exclusion criteria

• Diagnosed with neurological or psychiatric disorders (e.g., Alzheimer's, Dementia, Schizophrenia, etc.).
• Currently receiving hormone therapy.
• Experiencing menstrual irregularities due to reasons other than menopause.
• Unable to complete the scales due to visual impairment or significant cognitive limitations.

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Completed
• Study type: Observational
• Phase: N/A
• Start date: 2025-05-08
• Primary completion: 2025-07-16
• Last update posted: 2025-08-11
• First posted: 2025-05-18

Sponsor & contact

Lead sponsor: Merve Coskun (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Cognitive Function Changes and Severity of Brain Fog Symptoms (BFS) (At baseline (one-time assessment at enrollment))
  The primary outcome measure of this study is to assess changes in cognitive function and the severity of brain fog symptoms in women at different stages of menopause (peri-menopause, menopause, and post-menopause). The Brain Fog Scale allows participants to subjectively assess their brain fog symptoms, including forgetfulness, difficulty focusing, mental slowing, and trouble finding words. Measurement Content: Mental Fatigue: Feelings…
• Menopause-Specific Quality of Life (MENQOL) (At baseline (one-time assessment at enrollment))
  The primary outcome measure of this study is to evaluate the impact of menopause on the overall quality of life (QOL) in women at different stages of menopause (peri-menopause, menopause, and post-menopause). The MENQOL assesses various aspects of life that are influenced by menopause, including physical, psychosocial, sexual, and vasomotor symptoms.The MENQOL uses a 7-point Likert scale, with scores ranging…

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.